Inhibition of TNF-α Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes

DSpace/Manakin Repository

Inhibition of TNF-α Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes

Citable link to this page

 

 
Title: Inhibition of TNF-α Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes
Author: Wang, Zongwei; Cheng, Zhiyong; Cristofaro, Vivian; Li, Jijun; Xiao, Xingyuan; Gomez, Pablo; Ge, Rongbin; Gong, Edward; Strle, Klemen; Sullivan, Maryrose P.; Adam, Rosalyn M.; White, Morris F.; Olumi, Aria F.

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Z., Z. Cheng, V. Cristofaro, J. Li, X. Xiao, P. Gomez, R. Ge, et al. 2012. “Inhibition of TNF-α Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes.” Diabetes 61 (8): 2134-2145. doi:10.2337/db11-1763. http://dx.doi.org/10.2337/db11-1763.
Full Text & Related Files:
Abstract: Diabetic bladder dysfunction (DBD) is common and affects 80% of diabetic patients. However, the molecular mechanisms underlying DBD remain elusive because of a lack of appropriate animal models. We demonstrate DBD in a mouse model that harbors hepatic-specific insulin receptor substrate 1 and 2 deletions (double knockout [DKO]), which develops type 2 diabetes. Bladders of DKO animals exhibited detrusor overactivity at an early stage: increased frequency of nonvoiding contractions during bladder filling, decreased voided volume, and dispersed urine spot patterns. In contrast, older animals with diabetes exhibited detrusor hypoactivity, findings consistent with clinical features of diabetes in humans. The tumor necrosis factor (TNF) superfamily genes were upregulated in DKO bladders. In particular, TNF-α was upregulated in serum and in bladder smooth muscle tissue. TNF-α augmented the contraction of primary cultured bladder smooth muscle cells through upregulating Rho kinase activity and phosphorylating myosin light chain. Systemic treatment of DKO animals with soluble TNF receptor 1 (TNFRI) prevented upregulation of Rho A signaling and reversed the bladder dysfunction, without affecting hyperglycemia. TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that achieved with metformin alone, suggesting that therapies targeting TNF-α may have utility in reversing the secondary urologic complications of type 2 diabetes.
Published Version: doi:10.2337/db11-1763
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402324/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11855888
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters